Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Hutchmed China Ltd (13 HK)
Watchlist
177
Analysis
Industrials
•
Hong Kong
HUTCHMED (China) Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) markets its products worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Hutchmed China Ltd
•
29 Jun 2021 15:35
HCM Secondary Trading: NPMA Approvals Warrant a Pop on Debut
We look updates from HCM since it launched its book building. We note that the recent NMPA approval will result in a share price pop on debut.
Ke Yan, CFA, FRM
Follow
194 Views
Share
bullish
•
Thematic (Sector/Industry)
•
27 Jun 2021 08:56
China Healthcare Weekly (Jun.25)
This article analyzed the results of 5th national volume-based purchase, the new announcement on the centralized procurement of artificial joints,...
Xinyao (Criss) Wang
Follow
218 Views
Share
bullish
•
Hutchmed China Ltd
•
22 Jun 2021 08:38
Pre-IPO Hutchmed China Ltd (13.HK) - The Strength and the Concerns
The article analyzed Hutchmed in terms of its business analysis, financial performance, pipeline, comparison with other biotech companies, and also...
Xinyao (Criss) Wang
Follow
262 Views
Share
bullish
•
Hutchmed China Ltd
•
19 Jun 2021 17:09
HutchMed Secondary Listing: HK-ADS Premium/(Discount) Views
HutchMed has launched a $603 million secondary listing on HKEx. In this note, we will look at HutchMed’s potential HK-ADS premium/(discount).
Arun George
Follow
312 Views
Share
bullish
•
Hutchmed China Ltd
•
18 Jun 2021 16:08
HCM Secondary Listing: Not a Good Performer
After its failed listing attempt 2019, today HCM launched its book building to raise USD 590m in its secondary listing in Hong Kong. We look at...
Ke Yan, CFA, FRM
Follow
403 Views
Share
First
Previous
7
8
9
10
11
12
13
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x